223 related articles for article (PubMed ID: 29653268)
1. BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC.
MacDonagh L; Gray SG; Breen E; Cuffe S; Finn SP; O'Byrne KJ; Barr MP
Cancer Lett; 2018 Aug; 428():117-126. PubMed ID: 29653268
[TBL] [Abstract][Full Text] [Related]
2. Synergistic Roles of Curcumin in Sensitising the Cisplatin Effect on a Cancer Stem Cell-Like Population Derived from Non-Small Cell Lung Cancer Cell Lines.
Abdul Satar N; Ismail MN; Yahaya BH
Molecules; 2021 Feb; 26(4):. PubMed ID: 33670440
[TBL] [Abstract][Full Text] [Related]
3. Suppression of cancer relapse and metastasis by inhibiting cancer stemness.
Li Y; Rogoff HA; Keates S; Gao Y; Murikipudi S; Mikule K; Leggett D; Li W; Pardee AB; Li CJ
Proc Natl Acad Sci U S A; 2015 Feb; 112(6):1839-44. PubMed ID: 25605917
[TBL] [Abstract][Full Text] [Related]
4. Novel triple‑positive markers identified in human non‑small cell lung cancer cell line with chemotherapy-resistant and putative cancer stem cell characteristics.
Satar NA; Fakiruddin KS; Lim MN; Mok PL; Zakaria N; Fakharuzi NA; Abd Rahman AZ; Zakaria Z; Yahaya BH; Baharuddin P
Oncol Rep; 2018 Aug; 40(2):669-681. PubMed ID: 29845263
[TBL] [Abstract][Full Text] [Related]
5. NEAT1 contributes to the CSC-like traits of A549/CDDP cells via activating Wnt signaling pathway.
Jiang P; Xu H; Xu C; Chen A; Chen L; Zhou M; Haq IU; Wu X; Mariyam Z; Feng Q
Chem Biol Interact; 2018 Dec; 296():154-161. PubMed ID: 30291867
[TBL] [Abstract][Full Text] [Related]
6. Lusianthridin targeting of lung cancer stem cells via Src-STAT3 suppression.
Bhummaphan N; Petpiroon N; Prakhongcheep O; Sritularak B; Chanvorachote P
Phytomedicine; 2019 Sep; 62():152932. PubMed ID: 31100681
[TBL] [Abstract][Full Text] [Related]
7. Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor.
Hubbard JM; Grothey A
Drugs; 2017 Jul; 77(10):1091-1103. PubMed ID: 28573435
[TBL] [Abstract][Full Text] [Related]
8. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
Quan YH; Lim JY; Choi BH; Choi Y; Choi YH; Park JH; Kim HK
Cancer Chemother Pharmacol; 2019 Mar; 83(3):399-410. PubMed ID: 30515553
[TBL] [Abstract][Full Text] [Related]
9. PAK1 confers chemoresistance and poor outcome in non-small cell lung cancer via β-catenin-mediated stemness.
Chen MJ; Wu DW; Wang YC; Chen CY; Lee H
Sci Rep; 2016 Oct; 6():34933. PubMed ID: 27713506
[TBL] [Abstract][Full Text] [Related]
10. A redox-responsive nanosystem to suppress chemoresistant lung cancer through targeting STAT3.
Feng Q; Chen J; Huang J; Li X; Liu X; Xiao C; Zheng X; Chen X; Li J; Gu Z; Luo K; Xiao K; Li W
J Control Release; 2023 Nov; 363():349-360. PubMed ID: 37748583
[TBL] [Abstract][Full Text] [Related]
11. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells.
Hsu HS; Huang PI; Chang YL; Tzao C; Chen YW; Shih HC; Hung SC; Chen YC; Tseng LM; Chiou SH
Cancer; 2011 Jul; 117(13):2970-85. PubMed ID: 21225866
[TBL] [Abstract][Full Text] [Related]
12. Autophagy inhibition of cancer stem cells promotes the efficacy of cisplatin against non-small cell lung carcinoma.
Hao C; Liu G; Tian G
Ther Adv Respir Dis; 2019; 13():1753466619866097. PubMed ID: 31368411
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and activity of BBI608 derivatives targeting on stem cells.
Zhou Q; Peng C; Du F; Zhou L; Shi Y; Du Y; Liu D; Sun W; Zhang M; Chen G
Eur J Med Chem; 2018 May; 151():39-50. PubMed ID: 29604543
[TBL] [Abstract][Full Text] [Related]
14. Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1α mediated XPC transcription.
Liu Y; Wang X; Li W; Xu Y; Zhuo Y; Li M; He Y; Wang X; Guo Q; Zhao L; Qiang L
Oncogene; 2020 Nov; 39(45):6893-6905. PubMed ID: 32978517
[TBL] [Abstract][Full Text] [Related]
15. CXCR4 promotes cisplatin-resistance of non-small cell lung cancer in a CYP1B1-dependent manner.
Xie S; Tu Z; Xiong J; Kang G; Zhao L; Hu W; Tan H; Tembo KM; Ding Q; Deng X; Huang J; Zhang Q
Oncol Rep; 2017 Feb; 37(2):921-928. PubMed ID: 27922681
[TBL] [Abstract][Full Text] [Related]
16. The SOX9-Aldehyde Dehydrogenase Axis Determines Resistance to Chemotherapy in Non-Small-Cell Lung Cancer.
Voronkova MA; Rojanasakul LW; Kiratipaiboon C; Rojanasakul Y
Mol Cell Biol; 2020 Jan; 40(2):. PubMed ID: 31658996
[TBL] [Abstract][Full Text] [Related]
17. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
18. JARID2 promotes stemness and cisplatin resistance in non-small cell lung cancer via upregulation of Notch1.
Wang Q; Wu J; Wei H; Huang H; Huang Y; Fang H; Gong X; Sun J; Wu Y; Lei C; Yu J; Hu D
Int J Biochem Cell Biol; 2021 Sep; 138():106040. PubMed ID: 34246759
[TBL] [Abstract][Full Text] [Related]
19. Napabucasin (BBI608) eliminate AML cells in vitro and in vivo via inhibition of Stat3 pathway and induction of DNA damage.
Bi S; Chen K; Feng L; Fu G; Yang Q; Deng M; Zhao H; Li Z; Yu L; Fang Z; Xu B
Eur J Pharmacol; 2019 Jul; 855():252-261. PubMed ID: 31085238
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.
Wang L; Liu X; Ren Y; Zhang J; Chen J; Zhou W; Guo W; Wang X; Chen H; Li M; Yuan X; Zhang X; Yang J; Wu C
Cell Death Dis; 2017 Apr; 8(4):e2746. PubMed ID: 28406482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]